With an expected dip for 2023, the pharmaceutical company could see its mRNA technology win big over the long term -- and investors could be rewarded.
Here's what traders should do.
BMY is breaking out to a new high.
Let's review the charts and indicators.
BDX gets an upgrade, but are the charts healthy enough to recommend?
Here's why in recessions and bear markets, the right mega-cap stocks can offer security -- and good yields.
Let's review the charts and indicators to see.
This particular biotech company just saw its stock whacked but still holds a lot of promise.
The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.
Stabilization in the holdings of Cathie Wood's ARK Innovation ETF would be a positive in this trader's view.